Sangamo Therapeutics (SGMO) Presents On MPS II Biology, Standard Of Care And Rationale For The Development Of SB-913 - Slideshow
Aug. 02, 2018 2:06 PM ETSangamo Therapeutics, Inc. (SGMO)18 Comments
The following slide deck was published by Sangamo Therapeutics, Inc. in conjunction with this event.
This article was written by
Seeking Alpha's transcripts team is responsible for the development of all of our transcript-related projects. We currently publish thousands of quarterly earnings calls per quarter on our site and are continuing to grow and expand our coverage. The purpose of this profile is to allow us to share with our readers new transcript-related developments. Thanks, SA Transcripts Team